TARC Lentiviral Activation Particles (h): sc-401905-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- TARC Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- TARC Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by TARC Lentiviral Activation Plasmid (h) and TARC Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the CCL17 promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: TARC Antibody (AB98): sc-80339
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TARC Lentiviral Activation Particles (h) | sc-401905-LAC | 200 µl | $455.00 |
Human CCL17 encodes thymus and activation-regulated chemokine (TARC), a secreted CC chemokine that signals primarily through CCR4 to direct chemotaxis of Th2-polarized T cells, regulatory T cells, and other CCR4-positive leukocyte subsets. TARC production by dendritic cells, endothelial cells, and epithelial cells links innate sensing to adaptive trafficking and contributes to leukocyte positioning within inflamed tissues. This axis intersects with cytokine-driven inflammatory programs and regulates immune cell recruitment, activation state, and tissue residency. Dysregulated CCL17/TARC expression is frequently studied in allergic inflammation, asthma, atopic dermatitis, and other immune-mediated conditions where altered CCR4-dependent migration shapes local immune composition.
TARC Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient CCL17 upregulation across a broader range of human cell types.
TARC Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the CCL17 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous TARC expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native CCL17 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.